查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1781961

病毒载体疫苗市场（按疾病、按类型、按最终用户、按国家和地区）－2025 年至 2032 年全球产业分析、市场规模、市场份额及预测

Viral Vector Vaccines Market, By Disease, By Type, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 269 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年病毒载体疫苗市场规模价值 8.5043 亿美元，2025 年至 2032 年的复合年增长率为 15.93%。

病毒载体疫苗市场-市场动态

传染病流行率上升推动市场需求

新冠肺炎 (COVID-19)、流感和肝炎等传染病发生率的上升，推动了对有效疫苗的需求。世界卫生组织 (WHO) 的数据显示，疫苗每年可预防 200 万至 300 万人死亡，凸显了其在全球健康中的关键作用。此外，基因工程的不断进步促进了更高效病毒载体疫苗的研发。然而，儘管不良反应案例罕见，但仍有报道，导致公众对此持谨慎态度，预计这将阻碍未来几年的市场成长。相反，由于医疗基础设施的改善和疫苗接种意识的提高，发展中地区蕴藏着巨大的成长机会。

病毒载体疫苗市场—关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 15.93%

根据疾病细分，预计传染病将在 2024 年占据最大市场份额

根据类型细分，腺病毒是 2024 年的主要类型

按地区划分，北美是 2024 年的主要收入来源

病毒载体疫苗市场-区隔分析：

全球病毒载体疫苗市场根据疾病、类型、最终用户和地区进行细分。

根据疾病类型，市场分为四类：传染病、癌症、遗传性疾病和其他疾病。预计在预测期内，传染病领域将占据全球病毒载体疫苗市场的主要份额。这种主导地位主要源于全球传染病的高负担以及病毒载体平台在开发针对传染病的疫苗方面已证实的有效性。

根据类型，市场分为五类：腺相关病毒 (AAV)、腺病毒、慢病毒、逆转录病毒和其他病毒。预计腺病毒将在预测期内占据最大的市场份额。这主要是因为腺病毒因其强大的免疫原性、携带大量基因有效载荷的能力以及快速疫苗开发的适用性而被广泛应用。

病毒载体疫苗市场—地理洞察

北美地区占据全球病毒载体疫苗市场的最大份额。这一优势得益于其先进的医疗基础设施、雄厚的研发投入以及领先的製药和生物技术公司。此外，预计亚太地区将在全球市场中实现最快的成长，这得益于医疗保健投资的增加、传染病发病率的上升以及人们对先进治疗方案的认识的不断提高。

病毒载体疫苗市场-竞争格局：

全球对高效快速疫苗的需求不断增长，推动技术创新和策略性投资。各公司正致力于改进载体设计、提升安全性并扩大生产能力，以满足不断增长的需求。与研究机构和政府机构的合作已成为一种常见做法，旨在加速疫苗研发和监管批准。此外，各公司正在拓展产品线，将针对新兴传染病的疫苗纳入其中。此外，各公司也正在进行区域扩张和收购，以增强全球影响力并扩大先进疫苗平台的可及性。

最新动态：

2025年6月，ImmunoPrecise Antibodies Ltd. 利用其以人工智慧为基础的 LENSai™ 平台，鑑定出四种登革热病毒血清型共有的稳定表位。这项突破为基于表位靶向的通用登革热疫苗的研发提供了支持。

目录

第一章：病毒载体疫苗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 病毒载体疫苗市场（按疾病）
    • 病毒载体疫苗市场片段（按类型）
    • 病毒载体疫苗市场片段（按最终用户）
    • 病毒载体疫苗市场（按国家/地区）
    • 病毒载体疫苗市场（按地区）
  • 竞争洞察

第三章：病毒载体疫苗主要市场趋势

  • 病毒载体疫苗市场驱动因素
    • 市场驱动因素的影响分析
  • 病毒载体疫苗市场限制
    • 市场限制的影响分析
  • 病毒载体疫苗的市场机会
  • 病毒载体疫苗市场未来趋势

第四章：病毒载体疫苗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：病毒载体疫苗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：病毒载体疫苗市场格局

  • 病毒载体疫苗市占分析（2024年）
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：病毒载体疫苗市场－依疾病

  • 概述
    • 按疾病细分的份额分析
    • 传染病
    • 癌症
    • 遗传性疾病
    • 其他的

第八章：病毒载体疫苗市场－依类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 腺相关病毒（AAV）
    • 腺病毒
    • 慢病毒
    • 逆转录病毒
    • 其他的

第九章：病毒载体疫苗市场－依最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 製药和生物製药公司
    • 研究机构

第十章：病毒载体疫苗市场－按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美洲病毒载体疫苗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按疾病）
    • 北美市场规模和预测（按类型）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲病毒载体疫苗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按疾病）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区病毒载体疫苗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（按疾病）
    • 亚太地区市场规模及预测（按类型）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲病毒载体疫苗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按疾病）
    • 拉丁美洲市场规模及预测（按类型）
    • 拉丁美洲市场规模及预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲病毒载体疫苗主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依疾病）
    • MEA 市场规模和预测（按类型）
    • MEA 市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：病毒载体疫苗产业主要供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Advanced Bioscience Laboratories
    • Sanofi SA
    • CH Boehringer Sohn AG & Ko
    • Brammer Bio, LLC
    • GE Healthcare
    • Creative Biogene
    • Pfizer Inc.
    • Moderna Inc.
    • Sinovac Biotech Ltd.
    • CSL Ltd.
    • Astra Zeneca plc
    • GSK plc
    • Serum Institute of India Pvt. Ltd.
    • Merck & Co. Inc.
    • Novasep
    • Charles River Laboratories
    • Waisman Biomanufacturing
    • uniQure NV
    • Creative-Biogene
    • Addgene
    • Aldevron
    • Thermo Fisher Scientific Inc.
    • Spark Therapeutics Inc.
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5367

REPORT HIGHLIGHT

Viral vector vaccines market size was valued at US$ 850.43 Million in 2024, expanding at a CAGR of 15.93% from 2025 to 2032.

Viral vector vaccines use a harmless virus as a delivery system to introduce genetic material from a pathogen into the body. This genetic code instructs cells to produce a protein that triggers an immune response without causing disease. These vaccines mimic natural infection, training the immune system to recognize and fight the real virus if exposed later. They are widely used in preventing infectious diseases like COVID-19 and Ebola.

Viral Vector Vaccines Market- Market Dynamics

Increasing prevalence of infectious diseases to propel market demand

The rising incidence of infectious diseases such as COVID-19, influenza, and hepatitis is propelling the demand for effective vaccines. According to the World Health Organization (WHO), vaccines prevent 2 to 3 million deaths annually, highlighting their critical role in global health. In addition, continuous progress in genetic engineering has facilitated the development of more efficient viral vector vaccines. However, instances of adverse effects, although rare, have been reported, leading to public hesitance, which is predicted to hamper the market growth in the coming years. On the contrary, developing regions present significant growth opportunities due to improving healthcare infrastructure and rising awareness about vaccination.

Viral Vector Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.93% over the forecast period (2025-2032)

Based on Disease segmentation, infectious diseases was predicted to show maximum market share in the year 2024

Based on Type segmentation, adenovirus was the leading Type in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Vaccines Market- Segmentation Analysis:

The Global Viral Vector Vaccines Market is segmented on the basis of Disease, Type, End User, and Region.

The market is divided into four categories based on Disease: infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is expected to hold the major market share in the global viral vector vaccines market during the forecast period. This dominance is primarily driven by the high global burden of infectious diseases and the proven effectiveness of viral vector platforms in developing vaccines against them.

The market is divided into five categories based on Type: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, and others. The adenovirus segment is expected to account for the largest market share during the forecast period. This is mainly because adenoviruses are widely used due to their strong immunogenicity, ability to carry large genetic payloads, and suitability for rapid vaccine development.

Viral Vector Vaccines Market- Geographical Insights

The North America region holds the largest share of the global viral vector vaccines market. This dominance is attributed to its advanced healthcare infrastructure, substantial investments in research and development, and the presence of leading pharmaceutical and biotechnology companies. Besides, the Asia-Pacific region is projected to experience the fastest growth in the global market, driven by the increasing healthcare investments, a rising prevalence of infectious diseases, and growing awareness of advanced therapeutic options.

Viral Vector Vaccines Market- Competitive Landscape:

Rising global demand for effective and rapid-response vaccines is driving technological innovation and strategic investment. Companies are focusing on enhancing vector design, improving safety profiles, and expanding manufacturing capabilities to meet surging demand. Partnerships with research institutions and government bodies are common to accelerate development and regulatory approval. Additionally, players are diversifying product pipelines to include vaccines for emerging infectious diseases. Regional expansions and acquisitions are also being pursued to strengthen global presence and increase access to advanced vaccine platforms.

Recent Developments:

In June 2025, ImmunoPrecise Antibodies Ltd. identified a stable epitope common to all four dengue virus serotypes using its AI-powered LENSai(TM) platform. This breakthrough supports progress toward a universal dengue vaccine using epitope-based targeting.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Advanced Bioscience Laboratories
  • Sanofi S.A.
  • C.H. Boehringer Sohn AG & Ko
  • Brammer Bio, LLC
  • GE Healthcare
  • Creative Biogene
  • Pfizer Inc.
  • Moderna Inc.
  • Sinovac Biotech Ltd.
  • CSL Ltd.
  • Astra Zeneca plc
  • GSK plc
  • Serum Institute of India Pvt. Ltd.
  • Merck & Co. Inc.
  • Novasep
  • Charles River Laboratories
  • Waisman Biomanufacturing
  • uniQure N.V.
  • Creative-Biogene
  • Addgene
  • Aldevron
  • Thermo Fisher Scientific Inc.
  • Spark Therapeutics Inc.
  • Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

  • Infectious Diseases
  • Cancer
  • Genetic Disorders
  • Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adeno-associated virus (AAV)
  • Adenovirus
  • Lentivirus
  • Retrovirus
  • Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

GLOBAL VIRAL VECTOR VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector Vaccines Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector Vaccines Market Snippet by Disease
    • 2.1.2. Viral Vector Vaccines Market Snippet by Type
    • 2.1.3. Viral Vector Vaccines Market Snippet by End User
    • 2.1.4. Viral Vector Vaccines Market Snippet by Country
    • 2.1.5. Viral Vector Vaccines Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector Vaccines Key Market Trends

  • 3.1. Viral Vector Vaccines Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector Vaccines Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector Vaccines Market Opportunities
  • 3.4. Viral Vector Vaccines Market Future Trends

4. Viral Vector Vaccines Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector Vaccines Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Viral Vector Vaccines Market Landscape

  • 6.1. Viral Vector Vaccines Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector Vaccines Market - By Disease

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease, 2024 & 2032 (%)
    • 7.1.2. Infectious Diseases
    • 7.1.3. Cancer
    • 7.1.4. Genetic Disorders
    • 7.1.5. Others

8. Viral Vector Vaccines Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 8.1.2. Adeno-associated virus (AAV)
    • 8.1.3. Adenovirus
    • 8.1.4. Lentivirus
    • 8.1.5. Retrovirus
    • 8.1.6. Others

9. Viral Vector Vaccines Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 9.1.2. Pharmaceutical and Biopharmaceutical Companies
    • 9.1.3. Research Institutes

10. Viral Vector Vaccines Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Viral Vector Vaccines Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Viral Vector Vaccines Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Viral Vector Vaccines Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Viral Vector Vaccines Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Viral Vector Vaccines Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Viral Vector Vaccines Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Advanced Bioscience Laboratories
    • 11.2.2. Sanofi S.A.
    • 11.2.3. C.H. Boehringer Sohn AG & Ko
    • 11.2.4. Brammer Bio, LLC
    • 11.2.5. GE Healthcare
    • 11.2.6. Creative Biogene
    • 11.2.7. Pfizer Inc.
    • 11.2.8. Moderna Inc.
    • 11.2.9. Sinovac Biotech Ltd.
    • 11.2.10. CSL Ltd.
    • 11.2.11. Astra Zeneca plc
    • 11.2.12. GSK plc
    • 11.2.13. Serum Institute of India Pvt. Ltd.
    • 11.2.14. Merck & Co. Inc.
    • 11.2.15. Novasep
    • 11.2.16. Charles River Laboratories
    • 11.2.17. Waisman Biomanufacturing
    • 11.2.18. uniQure N.V.
    • 11.2.19. Creative-Biogene
    • 11.2.20. Addgene
    • 11.2.21. Aldevron
    • 11.2.22. Thermo Fisher Scientific Inc.
    • 11.2.23. Spark Therapeutics Inc.
    • 11.2.24. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us